In a nationally representative sample of older adults, this study characterizes changes in the prevalence of medication use and quantifies the frequency and types of potential major drug-drug interactions.
This Teachable Moment discusses the how the Centers for Disease Control and Prevention guidelines for opioid prescribing can play a major role in limiting the impact of this epidemic.
This population-based study examines whether the use of dipeptidylpeptidase-4 inhibitors and glucagon-like peptide 1 analogues is associated with an increased risk of incident bile duct and gallbladder disease in patients with type 2 diabetes mellitus.
This study found that few drug labels contained or referenced convincing evidence of clinical utility of biomarker testing, whereas many made recommendations based on biomarker test results. See also the Invited Commentary by Burke.
This study uses US Food and Drug Administration data to identify approved generic drugs manufactured between September 30, 1984, and January 11, 2016 and compares the effects of number of generic drugs associated with brand-name drugs.
A newly proposed US Food and Drug Administration guidance could undermine the agency's drug safety laws and regulations by allowing pharmaceutical companies to claim their drugs are less risky than stated in the approved label.
This survey study investigates attitudes toward prescribing generic drugs among internists and specialists in endocrinology, hematology, and infectious diseases.
This study examines national patterns to identify effects on opioid analgesic prescribing before and after the US Drug Enforcement Administration’s rescheduling of hydrocodone combination analgesic products.
To inform the debate about appropriate standards, Moore and Furberg studied the development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US FDA in 2008. Carpenter provides an Invited Commentary.
This cross-sectional study estimates potential savings through therapeutic substitution in terms of both overall and out-of-pocket expenditures of branded drugs when a generic in the same class with the same indication was available.
This study describes the development and validation of a screening instrument for drug use disorders and negative consequences of drug use for use in primary care clinics.
This Viewpoint questions the benefit-risk balance of vorapaxar use as a component of 3-drug antiplatelet therapy for cardiovascular disease.
This observational cohort study suggests that maintenance treatment with methadone or buprenorphine for opioid use disorders may be an important strategy to prevent the spread of hepatitis C virus (HCV) infection among young injection drug users.